Quarter
Charts
🇺🇸US Markets

Voyager Therapeutics, Inc.

VYGR

CIK 0001640266 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$15M
↑+144.3% +$9Mvs FY2024 (Q4)
Gross Profit
$15M
↑+144.3% +$9Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    0ROIC -50.1% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 7.64 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.15x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +144.3% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -228.9% · trend -426.5pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$3M
investment in PP&E
Stock-based comp (TTM)
$15M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$252M
everything owned
Total liabilities
$56M
everything owed
Stockholders' equity
$196M
shareholder claim

Recent performance · 48 quarters

Revenue↑+144.3% +$9M
$15M
Net Income↓-208.4% -$19M
$-28M
Free Cash Flow↓-303.9% -$471K
$-626K
Operating Margin↓-173.0pts
-228.9%

Drill down